XASX
CQT
Market cap5mUSD
Nov 02, Last price
0.01AUD
1D
-37.50%
1Q
-75.00%
Jan 2017
-99.27%
IPO
-99.94%
Name
CardieX Ltd
Chart & performance
P/E
—
P/S
0.81
EPS
—
Vol. 1Y
95.15%
Shs. 5Y
34.24%
Rev. 5Y
7.92%
Div Yld LY
—
Div Yld TTM
—
Revenues
6m
-42.39%
Net income
-13m
L+95.49%
CFO
-11m
L+41.12%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Conneqt Health Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that captures central hemodynamics and arterial stiffness for noninvasive measurement of vascular biomarkers including central aortic pressures and arterial stiffness indices. The company also provides medical devices and vascular biomarkers for hypertension, cardiovascular disease, and other vascular health disorders; and develops and sells medical devices, digital solutions, and wearables, home health, decentralized clinical trials, and remote patient monitoring. It sells its cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company was formerly known as CardieX Limited and changed its name to Conneqt Health Limited in September 2025. Conneqt Health Limited was founded in 1994 and is based in Sydney, Australia.
Key people
Executive Chairman of the Board · since 2019
Steve Braaten
Vice President - Operations · since 2023
Craig Cooper
Chief Executive Officer, Executive Director · since 2017
Catherine Liao
Chief Strategy Officer · since 2023
Louisa Ho
Company Secretary · since 2023
Randall Nelson
Independent Non-Executive Director · since 2015
Charlie Taylor
Non-Executive Independent Director · since 2024
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||